Core Viewpoint - The actual controller of Guizhou Bailing, Jiang Wei, has been placed under investigation by the China Securities Regulatory Commission (CSRC) for insider trading, information disclosure violations, and illegal stock transfers [6][8]. Group 1: Investigation Details - On December 3, Guizhou Bailing announced that Jiang Wei received a notice of investigation from the CSRC due to allegations of insider trading and information disclosure violations [6]. - The investigation is focused on Jiang Wei personally and is stated to have no impact on the company's daily operations or business activities [6]. - Guizhou Bailing has been previously investigated for information disclosure violations, with the CSRC launching an investigation in November 2024, the results of which are still pending [4][8]. Group 2: Company Background and Leadership - Guizhou Bailing was founded in 1999 and specializes in the research, production, and sales of traditional Chinese medicine, with notable products including "Yindan Xinnaotong Soft Capsules" and "Vitamin C Yinqiao Tablets" [10]. - Jiang Wei, born in 1961 and a graduate of Guizhou University of Traditional Chinese Medicine, has been the chairman of Guizhou Bailing since 2007 and led the company to become the first listed company in the traditional Chinese medicine sector in 2010 [7]. Group 3: Financial Performance - For the first three quarters of 2025, Guizhou Bailing reported a revenue of 2.102 billion yuan, a year-on-year decrease of 24.28%, and a net profit attributable to shareholders of 57 million yuan, down 35.6% year-on-year [14]. - As of December 3, the stock price of Guizhou Bailing was 5.57 yuan per share, with a total market capitalization of 7.785 billion yuan [14]. Group 4: Legal Disputes - Recent legal disputes involving Jiang Wei and Huachuang Securities have drawn significant attention, with Huachuang Securities filing lawsuits against Jiang Wei and others over a total amount of 1.4 billion yuan related to a rescue plan and stock pledge disputes [11]. - Jiang Wei has counter-sued, demanding that Huachuang Securities fulfill its obligations regarding the sale of pledged shares and compensation for losses incurred due to alleged malicious reporting [11].

Core Viewpoint - The actual controller of Guizhou Bailing, Jiang Wei, has been placed under investigation by the China Securities Regulatory Commission (CSRC) for insider trading, information disclosure violations, and illegal stock transfers [4][17]. Group 1: Investigation Details - Jiang Wei received a notice of investigation from the CSRC, which states that he is suspected of insider trading and violating information disclosure regulations [4][17]. - Guizhou Bailing clarified that the investigation pertains to Jiang Wei personally and will not affect the company's daily operations or business activities [4][17]. - The company will continue to monitor the situation and fulfill its information disclosure obligations as required by law [4][18]. Group 2: Background on Jiang Wei - Jiang Wei, born in 1961, graduated from Guizhou University of Traditional Chinese Medicine in 1982 and is currently the chairman of Guizhou Bailing [4][18]. - He has been instrumental in the company's development, leading the launch of several well-known traditional medicine products and overseeing its listing on the Shenzhen Stock Exchange in 2010 [4][18]. Group 3: Regulatory History - Guizhou Bailing has faced multiple regulatory actions in recent years, including corrective measures and warnings from the Guizhou Securities Regulatory Bureau due to issues with financial disclosures and internal controls [5][18]. - The company was previously investigated for information disclosure violations in November 2024, with the results of that investigation still pending [6][19]. Group 4: Legal Disputes - Jiang Wei is involved in a legal dispute with Huachuang Securities regarding a rescue plan and stock pledge disputes, with claims amounting to 1.4 billion yuan and 361 million yuan respectively [21][22]. - The disputes arose from allegations that Jiang Wei failed to fulfill obligations related to stock repurchase and repayment, leading to litigation [21][22]. - As of September 2025, Jiang Wei holds 17.55% of Guizhou Bailing's shares, while Huachuang Securities holds 11.54% through asset management plans [22]. Group 5: Financial Performance - For the first three quarters of 2025, Guizhou Bailing reported revenues of 2.102 billion yuan, a year-on-year decrease of 24.28%, and a net profit attributable to shareholders of 57 million yuan, down 35.6% year-on-year [23]. - As of December 3, 2025, the company's stock price was 5.57 yuan per share, with a total market capitalization of 7.785 billion yuan [24].

Core Viewpoint - Guizhou Bailing announced that its actual controller, Jiang Wei, is under investigation by the China Securities Regulatory Commission (CSRC) for insider trading and information disclosure violations, which is unrelated to the company's operations and will not impact its business activities [1][4]. Company Overview - Guizhou Bailing is engaged in the research, production, and sales of traditional Chinese medicine, with a registered capital of 1.4112 billion yuan and total assets of 7.059 billion yuan. The company was listed on the Shenzhen Stock Exchange in June 2010 and aims to strengthen its position in the traditional Chinese medicine sector [4][3]. Financial Performance - For the first three quarters of 2025, Guizhou Bailing reported revenue of 2.102 billion yuan, a year-on-year decrease of 24.28%, and a net profit attributable to shareholders of 57 million yuan, down 35.60% year-on-year [5]. - The company experienced a significant decline in revenue and net profit in the first half of 2025, with revenue of 1.462 billion yuan, a decrease of 31.77%, and a net profit of 52 million yuan, down 40.73% year-on-year. The decline in revenue from traditional Chinese medicine products, which account for over 80% of total revenue, was particularly notable, with a year-on-year decrease of 37.07% [4][5]. - Despite a year-on-year increase in revenue and net profit in the third quarter, the overall performance for the first three quarters remained significantly lower due to poor results in the first half of the year [4].

Group 1 - Dongfang Electric announced that three executives plan to reduce their holdings by a total of no more than 30,000 shares due to personal financial needs [1] - Yahu Pharmaceutical's APL-1401 clinical trial data was presented at the 19th European Colorectal Congress, indicating progress in treating moderate to severe ulcerative colitis [1] - Guizhou Bai Ling's actual controller is under investigation by the China Securities Regulatory Commission for insider trading and information disclosure violations [3] Group 2 - Bairen Medical's ePTFE pericardial membrane product has been approved for registration, ending the reliance on imports for this product in the domestic market [4] - Qianxin received approval for a total of 2 billion yuan in technology innovation bonds, with plans to issue medium-term notes and short-term financing bonds [6] - Tengjing Technology's shareholder plans to reduce holdings by no more than 1.96% of the company's shares [7] Group 3 - Yuntianhua's subsidiary is required to pay 386 million yuan in overdue taxes and penalties, which will impact the company's net profit for 2025 [8] - Jianyou Pharmaceutical's propofol emulsion injection has received FDA approval in the United States [9] - Suzhou Gaoxin successfully acquired land use rights for a residential project for 360 million yuan [9] Group 4 - Chalco International's subsidiary won a bid for a 3.03 billion yuan electrolytic aluminum project [11] - Tai Long Pharmaceutical's stock will continue to be suspended due to potential changes in control as the major shareholder is planning a share transfer [12] - Qianli Technology reported a 63.44% year-on-year increase in automobile sales for November, although new energy vehicle sales decreased by 43.98% [13] Group 5 - Fosun Pharma's innovative drug FXS0887 has received approval for a Phase I clinical trial for advanced malignant solid tumors [14] - Guoen Co. has obtained approval for a project to produce 20,000 square meters of aviation-grade acrylic glass, with a total investment of 560 million yuan [15] - Guofa Co.'s chairman resigned due to personal reasons [17] Group 6 - Shanghai Construction won a bid for a state-owned construction land use right for 264 million yuan [18] - Weixin Kang's subsidiary received approval for a clinical trial of lidocaine cream for local anesthesia [20] - Sanxing Medical's subsidiary is a candidate for a 152 million yuan transformer procurement project for the State Grid [20] Group 7 - People's Daily announced the resignation of its president due to work changes, while retaining other leadership roles [21] - Beibu Gulf Port reported a 0.29% year-on-year increase in cargo throughput for November [22] - Chongqing Construction won three engineering projects with a total value of approximately 2.773 billion yuan [23] Group 8 - Xingyu Co. is planning to issue H-shares and list on the Hong Kong Stock Exchange [24] - Huajian Group signed a design contract worth 160 million yuan for a comprehensive project [25] - Wankai New Materials plans to invest 350 million yuan in a technical transformation project for producing 100,000 tons of adipic acid [26] Group 9 - Kaipuyun received a government subsidy of 18 million yuan, which is 87.43% of its net profit for the last audited fiscal year [28] - Ningbo Port expects a 10.8% year-on-year increase in container throughput for November [30] - An Cai High-Tech plans to invest 498 million yuan to upgrade its photovoltaic glass production line [32] Group 10 - Shunhao Co. stated that its existing business has not generated synergies with the rail business, which faces various risks [34] - Yihualu plans to publicly transfer 35% of its stake in Liaoyun Company [35] - ST Wanfang's shareholder plans to reduce holdings by no more than 3% of the company's shares [36] Group 11 - Youyou Food's shareholder plans to reduce holdings by no more than 110,000 shares [38] - Hengtong Optic-Electric's incentive fund has spent 49.98 million yuan to purchase company shares [41] - Zoli Pharmaceutical plans to issue convertible bonds to raise no more than 1.556 billion yuan for various projects [42]

12月3日，贵州百灵公告，收到公司实际控制人姜伟的通知，其于近日收到中国证券监督管理委员会下 发的《立案告知书》。 按照该告知书，姜伟因涉嫌内幕交易、信息披露违法、违反限制性规定转让股票，根据《中华人民共和 国证券法》《中华人民共和国行政处罚法》等法律法规，中国证监会决定对其进行立案。 贵州百灵表示，本次立案系对公司实际控制人姜伟个人的调查，与公司日常经营管理和业务活动无关， 不会对上市公司及子公司生产经营活动产生影响。 贵州百灵今日收跌0.89%，报5.57元。 编 辑丨瑜见 ...

#贵州百灵实控人涉内幕交易等被证监会立案#【贵州百灵：因涉嫌内幕交易等，实控人姜伟被证监会立 案】贵州百灵公告，公司收到公司实际控制人姜伟的通知，其于近日收到中国证券监督管理委员会下发 的《立案告知书》。按照该告知书，姜伟因涉嫌内幕交易、信息披露违法、违反限制性规定转让股票， 根据《中华人民共和国证券法》《中华人民共和国行政处罚法》等法律法规，中国证监会决定对其进行 立案。本次立案系对公司实际控制人姜伟个人的调查，与公司日常经营管理和业务活动无关，不会对上 市公司及子公司生产经营活动产生影响。（第一财经） ...

贵州百灵12月3日公告，公司收到公司实际控制人姜伟的通知，其于近日收到中国证券监督管理委员会 下发的《立案告知书》。按照该告知书，姜伟先生因涉嫌内幕交易、信息披露违法、违反限制性规定转 让股票，中国证监会决定对其进行立案。本次立案系对公司实际控制人姜伟个人的调查，与公司日常经 营管理和业务活动无关，不会对上市公司及子公司生产经营活动产生影响。 ...

贵州百灵表示，本次立案系对公司实际控制人姜伟个人的调查，与公司日常经营管理和业务活动无关，不会对上市公司及子公司生产经营活动产生影响。 贵州百灵今日收跌0.89%，报5.57元。 12月3日，贵州百灵公告，收到公司实际控制人姜伟的通知，其于近日收到中国证券监督管理委员会下发的《立案告知书》。 按照该告知书，姜伟因涉嫌内幕交易、信息披露违法、违反限制性规定转让股票，根据《中华人民共和国证券法》《中华人民共和国行政处罚法》等法律 法规，中国证监会决定对其进行立案。 编辑丨瑜见 ...

贵州百灵（002424）(002424.SZ)发布公告，公司收到公司实际控制人姜伟先生的通知，其于近日收到 中国证券监督管理委员会(以下简称"中国证监会")下发的《立案告知书》(编号：证监立案字 03720252005号)。按照该告知书，姜伟先生因涉嫌内幕交易、信息披露违法、违反限制性规定转让股 票，根据《中华人民共和国证券法》《中华人民共和国行政处罚法》等法律法规，中国证监会决定对其 进行立案。 ...

证券代码：002424 证券简称：贵州百灵 公告编号：2025-047 贵州百灵企业集团制药股份有限公司（以下简称"公司"）收到 公司实际控制人姜伟先生的通知，其于近日收到中国证券监督管理委 员会（以下简称"中国证监会"）下发的《立案告知书》（编号：证 监立案字03720252005号）。按照该告知书，姜伟先生因涉嫌内幕交 易、信息披露违法、违反限制性规定转让股票，根据《中华人民共和 国证券法》《中华人民共和国行政处罚法》等法律法规，中国证监会 决定对其进行立案。 本次立案系对公司实际控制人姜伟先生个人的调查，与公司日常 经营管理和业务活动无关，不会对上市公司及子公司生产经营活动产 生影响。立案调查期间，姜伟先生将积极配合中国证监会的立案调查 工作。公司将持续关注上述事项的进展情况，并严格按照相关法律法 规及监管要求及时履行信息披露义务。 公司所有信息均以在指定信息披露媒体披露的信息为准，敬请广 大投资者理性投资，注意投资风险。 特此公告。 贵州百灵企业集团制药股份有限公司 董 事 会 2025年12月3日 贵州百灵企业集团制药股份有限公司 关于实际控制人收到中国证券监督管理委员会立案 告知书的公告 本公司及 ...